FrancophonIA/ELRC3.0 huggingface dataset:
English: IDNT was a double blind, controlled, morbidity and mortality trial comparing irbesartan, amlodipine and placebo.
Croatian: IDNT je bila dvostruko slijepa, kontrolirana studija morbiditeta i mortaliteta u kojoj su uspoređivani irbesartan, amlodipin i placebo.
English: Irbesartan has been studied in paediatric populations aged 6 to 16 years old but the current data are insufficient to support an extension of the use in children until further data become available (see sections 4.8, 5.1 and 5.2).
Croatian: Irbesartan je ispitivan na pedijatrijskoj populaciji u dobi od 6 do 16 godina, ali trenutni podaci nisu dostatni da bi podržali proširenje primjene na djecu, sve dok ne budu dostupni i daljnji podaci (vidjeti dijelove 4.8, 5.1 i 5.2).
English: When the individual components of the primary endpoint were analysed, no effect in all cause mortality was observed, while a positive trend in the reduction in ESRD and a significant reduction in doubling of serum creatinine were observed.
Croatian: Kada su se analizirale individualne komponente primarnog ishoda, nisu zabilježeni učinci na sve uzroke smrtnosti, dok je zabilježen pozitivan trend u smanjenju terminalne faze bubrežne bolesti i značajno smanjenje u udvostručavanju serumskog kreatinina.
English: When driving vehicles or operating machines, it should be taken into account that dizziness or weariness may occur during treatment.
Croatian: Prilikom upravljanja vozilima ili rukovanja strojevima, potrebno je uzeti u obzir mogućnost pojave omaglice ili umora tijekom liječenja.
English: If you experience these, talk to your doctor before attempting to drive or use machines.
Croatian: Ako to osjetite, savjetujte se sa svojim liječnikom prije nego što pokušate voziti ili upravljati strojevima.
English: Ifirmasta is unlikely to affect your ability to drive or use machines.
Croatian: Nije vjerojatno da bi Ifirmasta utjecala na Vašu sposobnost upravljanja vozilima ili rukovanja strojevima.
English: Such conditions should be corrected before the administration of Ifirmasta.
Croatian: Takva stanja treba korigirati prije primjene Ifirmaste.
English: Pharmacotherapeutic group: angiotensin II antagonist, plain, ATC code: C09CA04.
Croatian: Farmakoterapijska skupina: antagonisti angiotenzina II, čisti, ATK oznaka: C09CA04.
English: Although consideration should be given to initiating therapy with 75 mg in patients over 75 years of age, dose adjustment is not usually necessary for older people.
Croatian: Iako za bolesnike starije od 75 godina treba razmotriti započinjanje terapije dozom od 75 mg, dozu obično nije potrebno prilagoditi u starijih osoba.
English: Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP.
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na pakiranju i blisteru iza oznake „EXP“.
English: Activated charcoal may be useful in the treatment of overdosage.
Croatian: Za liječenje predoziranja može biti koristan aktivni ugljen.
English: Ifirmasta is indicated in adults for the treatment of essential hypertension.
Croatian: Ifirmasta je indicirana za liječenje esencijalne hipertenzije u odraslih.
English: In the 26-week open-label period of this trial the most frequent laboratory abnormalities observed were creatinine increases (6.5%) and elevated CK values in 2% of child recipients.
Croatian: U otvorenom razdoblju ovog ispitivanja, u trajanju od 26 tjedana, najčešće opažene laboratorijske abnormalnosti bile su povećana koncentracija kreatinina (6,5%) i povišene vrijednosti CK u 2% djece koja su primila lijek.
English: In particular, they appeared less favourable in women and non-white subjects (see section 5.1).
Croatian: Posebice je bio slabije izražen u žena i bolesnika koji nisu pripadali bijeloj rasi (vidjeti dio 5.1).
English: In particular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive effect with Ifirmasta (see section 4.5).
Croatian: Osobito se pokazalo da dodavanje diuretika kao što je hidroklorotiazid ima aditivni učinak uz Ifirmastu (vidjeti dio 4.5).
English: The frequency of the side effects listed below is defined using the following convention: Very common: may affect more than 1 in 10 people Common: may affect up to 1 in 10 people
Croatian: Učestalost dolje navedenih nuspojava definirana je na sljedeći način: Vrlo često: mogu se javiti u više od 1 na 10 osoba
English: Ifirmasta is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.
Croatian: Ifirmasta se ne preporučuje majkama koje doje, a Vaš liječnik može izabrati drugu terapiju ako želite dojiti, osobito ako se radi o dojenju novorođenčeta ili nedonoščeta.
English: Irbesartan significantly reduced the relative risk in the primary combined endpoint of doubling serum creatinine, end-stage renal disease (ESRD) or allcause mortality.
Croatian: Irbesartan je značajno snizio relativni rizik u primarnoj kombiniranoj mjeri ishoda udvostručenog serumskog kreatinina, terminalne faze bubrežne bolesti ili svih uzroka mortaliteta.
English: Ifirmasta at a dose of 150 mg once daily generally provides a better 24 hour blood pressure control than 75 mg.
Croatian: Doza od 150 mg Ifirmaste jedanput na dan općenito osigurava bolju kontrolu krvnog tlaka u razdoblju od 24 sata nego doza od 75 mg.
English: No dosage adjustment is necessary in older people.
Croatian: Stoga, nije potrebna prilagodba doze u starijih osoba.
English: The maximal blood pressure lowering effect should be reached 4-6 weeks after beginning treatment.
Croatian: Maksimalni učinak na sniženje krvnog tlaka trebao bi se postići za 4-6 tjedana od početka liječenja.
English: In this case your doctor may perform regular blood tests, especially for measuring blood potassium levels in case of poor kidney function, - if you are going to have an operation (surgery) or be given anaesthetics,
Croatian: U tom će Vam slučaju Vaš liječnik možda raditi redovite pretrage krvi, posebno određivanje koncentracije kalija u krvi u slučaju oslabljene funkcije bubrega, - ako trebate ići na bilo kakav kirurški zahvat ili trebate primiti anestetike,
English: Blister (PVC/PE/PVDC/Alu): 56 x 1 film-coated tablets in perforated unit dose blisters in box.
Croatian: Blister (PVC/PE/PVDC/Al): 56 x 1 filmom obloženih tableta u perforiranim blisterima djeljivim na jedinične doze, u kutiji.
English: hypersensitivity reactions such as angioedema, rash, urticaria, anaphylactic reaction, anaphylactic shock
Croatian: reakcije preosjetljivosti kao što su angioedem, osip, urtikarija, anafilaktička reakcija, anafilaktički šok
English: How to take Ifirmasta
Croatian: Kako uzimati Ifirmastu
English: The usual dose is 150 mg once a day (two tablets a day).
Croatian: Uobičajena doza iznosi 150 mg jednom na dan (dvije tablete na dan).
English: Polyvinyl alcohol Titanium dioxide (E171) Macrogol 3000
Croatian: Film ovojnica: poli (vinilni alkohol) titanijev dioksid (E171) makrogol 3000 talk
English: The usual dose is 150 mg once a day.
Croatian: Uobičajena doza iznosi 150 mg jednom na dan.
English: While this is not documented with Ifirmasta, a similar effect should be anticipated with angiotensin-II receptor antagonists.
Croatian: Iako to još nije potvrđeno za Ifirmastu, sličan učinak može se očekivati s antagonistima receptora angiotenzina II.
English: vertigo, headache
Croatian: vrtoglavica, glavobolja
English: The blood pressure lowering effect of irbesartan is evident within 1-2 weeks, with the maximal effect occurring by 4-6 weeks after start of therapy.
Croatian: Učinak irbesartana na snižavanje krvnog tlaka vidljiv je unutar 1-2 tjedna, s maksimalnim učinkom za 4-6 tjedana od početka terapije.
English: Blister (PVC/PE/PVDC/Alu): 14, 28, 30, 56, 84, 90 or 98 film-coated tablets in box are available.
Croatian: Blister (PVC/PE/PVDC/Al): 14, 28, 30, 56, 84, 90 ili 98 filmom obloženih tableta, u kutiji.
English: If you get any of these symptoms or get short of breath, stop taking irbesartan and contact your doctor immediately.
Croatian: Ako primijetite bilo koji od ovih simptoma ili nedostatak zraka, prestanite uzimati irbesartan i odmah se javite liječniku.
English: You may need to have blood checks if you take: - potassium supplements, - salt substitutes containing potassium, - potassium-sparing medicines (such as certain diuretics), - medicines containing lithium.
Croatian: Pretrage krvi mogu biti neophodne ako uzimate: - nadomjestke kalija, - nadomjestke soli koje sadrže kalij, - lijekove koji čuvaju kalij (kao što su neki diuretici) ili - lijekove koji sadrže litij.
English: In patients insufficiently controlled with 150 mg once daily, the dose of Ifirmasta can be increased to 300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1).
Croatian: U bolesnika u kojih se bolest ne može dostatno kontrolirati dozom od 150 mg jedanput na dan, doza Ifirmaste može se povećati na 300 mg ili se mogu dodati drugi antihipertenzivi (vidjeti dijelove 4.3, 4.4, 4.5 i 5.1).
English: Following oral or intravenous administration of
Croatian: Nakon oralne ili intravenske primjene
English: Ifirmasta belongs to a group of medicines known as angiotensin-II receptor antagonists.
Croatian: Ifirmasta pripada skupini lijekova koja se naziva antagonisti receptora angiotenzina II.
English: In vitro studies indicate that irbesartan is primarily oxidised by the cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.
Croatian: In vitro ispitivanja upućuju da se irbesartan primarno oksidira pomoću enzima CYP2C9 citokroma P450 dok izoenzim CYP3A4 ima neznatan učinak.
English: Because no information is available regarding the use of Ifirmasta during breast-feeding, Ifirmasta is not recommended and alternative treatments with better established safety profiles during breastfeeding are preferable, especially while nursing a newborn or preterm infant.
Croatian: Budući da nema dostupnih podataka o primjeni Ifirmaste tijekom dojenja, ne preporučuje se primjena Ifirmaste tijekom dojenja i prednost treba dati drugoj terapiji s boljim profilom sigurnosti primjene, osobito kada se doji novorođenče ili nedonošče.
English: Rebound hypertension has not been observed.
Croatian: Nije zabilježena pojava veće hipertenzije (tzv. rebound).
English: Diuretics and other antihypertensive agents:
Croatian: Diuretici i drugi antihipertenzivni lijekovi:
English: Your doctor may need to change your dose and/or to take other precautions: - If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Ifirmasta” and “Warnings and precautions”).
Croatian: Liječnik će Vam možda morati promijeniti dozu i/ili poduzeti druge mjere opreza: - Ako uzimate ACE inhibitor ili aliskiren (vidjeti također informacije pod naslovima
English: Based on its pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive and use machines.
Croatian: Na temelju njegovih farmakodinamičkih svojstava, nije vjerojatno da bi irbesartan utjecao na sposobnost upravljanja vozilima i rada sa strojevima.
English: It is unknown whether irbesartan or its metabolites are excreted in human milk.
Croatian: Nije poznato izlučuju li se irbesartan ili njegovi metaboliti u majčino mlijeko.
English: The following table presents the adverse medicinal product reactions that were reported in placebocontrolled trials in which 1,965 hypertensive patients received irbesartan.
Croatian: Sljedeća tablica prikazuje nuspojave prijavljene u placebom kontroliranim ispitivanjima, u kojima je 1965 hipertenzivnih bolesnika primalo irbesartan.
English: - The other ingredients are mannitol, hydroxypropylcellulose, low-substituted hydroxypropyl cellulose (LH-21), low-substituted hydroxypropyl cellulose (LH-11), talc, macrogol 6000, castor oil, hydrogenated in the core of tablet and polyvinyl alcohol, titanium dioxide (E171), macrogol 3000 and talc in film-coating.
Croatian: - Drugi sastojci su manitol, hidroksipropilceluloza, nisko supstituirana hidroksipropilceluloza (LH-21), nisko supstituirana hidroksipropilceluloza (LH-11), talk, makrogol 6000 i hidrogenirano ricinusovo ulje u jezgri tablete te polivinilni alkohol, titanijev dioksid (E171), makrogol 3000 i talk u film ovojnici.
English: When angiotensin II antagonists are administered simultaneously with non-steroidal antiinflammatory medicinal products (i.e. selective COX-2 inhibitors, acetylsalicylic acid (> 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.
Croatian: Kada se antagonisti angiotenzina II primjenjuju istodobno s nesteroidnim protuupalnim lijekovima (tj. selektivnim inhibitorima COX2, acetilsalicilatnom kiselinom (> 3 g/dan) i neselektivnim NSAIL) moguć je oslabljeni antihipertenzivni učinak.
English: Reproductive system and breast disorders: Uncommon: sexual dysfunction
Croatian: Poremećaji reproduktivnog sustava i dojki: Manje često: seksualna disfunkcija
English: Ifirmasta prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower.
Croatian: Ifirmasta sprječava vezanje angiotenzina II na te receptore, uzrokujući opuštanje krvnih žila i sniženje krvnog tlaka.
English: Talk to your doctor or pharmacist before taking Ifirmasta and if any of the following apply to you: - if you get excessive vomiting or diarrhoea, - if you suffer from kidney problems, - if you suffer from heart problems, - if you receive Ifirmasta for diabetic kidney disease.
Croatian: Obratite se svom liječniku prije nego uzmete Ifirmastu ako se nešto od dolje navedenog odnosi na Vas: - ako Vas muči prekomjerno povraćanje ili proljev, - ako imate problema s bubrezima, - ako imate srčanih problema, - ako uzimate Ifirmastu zbog dijabetičke bolesti bubrega.
English: AngiotensinII is a substance produced in the body which binds to receptors in blood vessels causing them to tighten.
Croatian: Angiotenzin II je tvar koja se stvara u tijelu i veže se na receptore u krvnim žilama te uzrokuje njihovo sužavanje.
English: As is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive patients have notably less response to irbesartan monotherapy.
Croatian: Kao što je to slučaj s ostalim lijekovima koji utječu na renin-angiotenzinski sustav, hipertenzivni bolesnici crne rase znatno slabije reagiraju na monoterapiju irbesartanom.
English: In patients with high blood pressure and type 2 diabetes with renal disease, dizziness when getting up from a lying or sitting position, low blood pressure when getting up from a lying or sitting position, pain in joints or muscles and decreased levels of a protein in the red blood cells (haemoglobin) were also reported.
Croatian: U bolesnika s visokim krvnim tlakom i šećernom bolešću tipa 2 i bubrežnom bolešću također su prijavljeni omaglica i nizak krvni tlak nakon podizanja iz sjedećeg ili ležećeg položaja, bol u zglobovima ili mišićima i smanjene razine proteina u crvenim krvnim stanicama (hemoglobina).
English: Ifirmasta is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
Croatian: Ifirmasta se ne preporučuje uzimati u ranoj trudnoći i ne smije se uzimati ako ste trudni duže od 3 mjeseca jer može ozbiljno naškoditi Vašem djetetu ako se primjenjuje u tom stadiju (vidjeti dio o trudnoći).
English: In a randomised trial of 318 hypertensive children and adolescents aged 6 to 16 years, the following adverse reactions occurred in the 3-week double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%).
Croatian: U trotjednoj dvostruko slijepoj fazi randomiziranog kliničkog ispitivanja u koje je bilo uključeno 318 djece i adolescenata s hipertenzijom u dobi od 6 do 16 godina pojavile su se sljedeće nuspojave: glavobolja (7,9%), hipotenzija (2,2%), omaglica (1,9%), kašalj (0,9%).
English: IRMA 2 was a placebo-controlled double blind morbidity study in 590 patients with type 2 diabetes, microalbuminuria (30-300 mg/day) and normal renal function (serum creatinine ≤ 1.5 mg/dl in males and < 1.1 mg/dl in females).
Croatian: IRMA 2 bila je placebom kontrolirana, dvostruko slijepa studija morbiditeta u 590 bolesnika sa šećernom bolešću tipa 2, mikroalbuminurijom (30-300 mg/dan) i normalnom bubrežnom funkcijom (serumski kreatinin ≤ 1,5 mg/dl u muškaraca i < 1,1 mg/dl u žena).
English: The concomitant use of Ifirmasta with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Croatian: Istodobna primjena Ifirmaste s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
English: Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting.
Croatian: Simptomatska hipotenzija, posebice nakon prve doze, može se pojaviti u bolesnika s hipovolemijom i/ili hiponatrijemijom zbog snažne diuretske terapije, restrikcijske dijete sa smanjenim unosom soli, proljeva ili povraćanja.
English: Approximately 33% of patients in the irbesartan group reached the primary renal composite endpoint compared to 39% and 41% in the placebo and amlodipine groups [20% relative risk reduction versus placebo (p = 0.024) and 23% relative risk reduction compared to amlodipine (p = 0.006)].
Croatian: Oko 33% bolesnika u irbesartan skupini dostiglo je primarni kompozitni ishod za bubrežnu bolest, u usporedbi s 39% u placebo i 41% u amlodipin skupini [20% smanjenje relativnog rizika u odnosu na placebo (p=0,024) i 23% smanjenje relativnog rizika u usporedbi s amplodipinom (p=0,006)].
English: The pharmacokinetics of irbesartan were evaluated in 23 hypertensive children after the administration of single and multiple daily doses of irbesartan (2 mg/kg) up to a maximum daily dose of 150 mg for four weeks.
Croatian: Farmakokinetika irbesartana proučavana je tijekom 4 tjedna na 23 djece s hipertenzijom nakon primjene jednokratne i višekratnih dnevnih doza (2 mg/kg), do maksimalne dnevne doze od 150 mg irbesartana.
English: Over a subsequent two week period where patients were re-randomized to either active medicinal product or placebo, patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on all doses of irbesartan (see section 4.2).
Croatian: Tijekom sljedeća dva tjedna kada su bolesnici ponovo randomizirani ili na lijek ili na placebo, bolesnici na placebu imali su porast od 2,4 i 2,0 mmHg za SeSBP i SeDBP, u usporedbi s promjenama od +0,1 i -0,3 mmHg za bolesnike na svim dozama irbesartana (vidjeti dio 4.2).
English: There is no experience regarding the administration of Ifirmasta in patients with a recent kidney transplantation.
Croatian: Nema iskustava s primjenom Ifirmaste u bolesnika kojima je nedavno transplantiran bubreg.
English: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Croatian: Ako ste trudni ili dojite, mislite da bi mogli biti trudni ili planirate imati dijete, obratite se svom liječniku ili ljekarniku prije uzimanja ovog lijeka.
English: Based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and is, therefore, not recommended (see section 4.4).
Croatian: Na temelju iskustva s ostalim lijekovima koji utječu na renin-angiotenzinski sustav, istodobno uzimanje diuretika koji štede kalij, nadomjestaka kalija, nadomjestaka soli koji sadrže kalij ili ostalih lijekova koji mogu povećati serumsku razinu kalija (npr. heparin) može izazvati porast serumskog kalija te se, stoga, ne preporučuje (vidjeti dio 4.4).
English: In patients not adequately controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood pressure reduction at trough of 7-10/3-6 mm Hg (systolic/diastolic).
Croatian: U bolesnika koji nisu odgovarajuće kontrolirani samim irbesartanom, dodavanje niske doze hidroklorotiazida (12,5 mg) irbesartanu jednom dnevno rezultira daljnjim placebo-prilagođenim snižavanjem krvnog tlaka pri minimalnoj vrijednosti od 7-10/3-6 mmHg (sistolički/dijastolički).
English: Undesirable effects where the frequency is not known are: feeling of spinning, headache, taste disturbance, ringing in the ears, muscle cramps, pain in joints and muscles, reduced number of platelets, abnormal liver function, increased blood potassium levels, impaired renal function, inflammation of small blood vessels mainly affecting the skin (a condition known as leukocytoclastic vasculitis) and severe allergic reactions (anaphylactic shock).
Croatian: Nuspojave čija učestalost nije poznata su: vrtoglavica, glavobolja, poremećaji okusa, zvonjenje u ušima, grčevi u mišićima, bol u zglobovima i mišićima, smanjen broj krvnih pločica, poremećaj funkcije jetre, povišena razina kalija u krvi, oslabljena funkcija bubrega, upala malih krvnih žila koja uglavnom zahvaća kožu (stanje poznato kao leukocitoklastični vaskulitis) i teške alergijske reakcije (anafilaktički šok).
English: Lithium The combination of lithium and Ifirmasta is not recommended (see section 4.5).
Croatian: Litij Ne preporučuje se kombinacija litija i Ifirmaste (vidjeti dio 4.5).
English: You must tell your doctor if you think you are (or might become) pregnant.
Croatian: Morate obavijestiti svog liječnika ako mislite da ste trudni (ili biste mogli ostati trudni).
English: Non-steroidal anti-inflammatory medicinal products:
Croatian: Nesteroidni protuupalni lijekovi:
English: Ifirmasta is for oral use.
Croatian: Ifirmasta je namijenjena za primjenu kroz usta.
English: When irbesartan is administered concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response in black patients approaches that of white patients.
Croatian: Kada se irbesartan primjenjuje istodobno s niskom dozom hidroklorotiazida (npr. 12,5 mg dnevno), antihipertenzivni odgovor u bolesnika crne rase se približava onom u bolesnika bijele rase.
English: Terms marked with a star (*) refer to the adverse reactions that were additionally reported in > 2% of diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria and in excess of placebo.
Croatian: Pojmovi označeni zvjezdicom (*) odnose se na nuspojave koje su dodatno prijavljene u više od 2% bolesnika sa šećernom bolešću i hipertenzijom s kroničnom insuficijencijom bubrega i manifestnom proteinurijom i to češće nego kod placeba.
English: Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with Ifirmasta (see section 4.4).
Croatian: Prethodno liječenje visokim dozama diuretika može dovesti do smanjenja volumena i rizika od pojave hipotenzije prilikom uvođenja terapije Ifirmastom (vidjeti dio
English: It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 and 5.1).
Croatian: Također je indicirana za liječenje bubrežne bolesti u odraslih bolesnika s hipertenzijom i šećernom bolešću tipa 2 u sklopu antihipertenzivne terapije (vidjeti dijelove 4.3, 4.4, 4.5 i 5.1).